BTAI logo

BioXcel Therapeutics, Inc. Common Stock


BTAI: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.


Show BTAI Financials

Consumer Interest
SEC Filings

Recent trades of BTAI by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by BTAI's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard

Number of mentions of BTAI in WallStreetBets Daily Discussion


Recent insights relating to BTAI

CNBC Recommendations

Recent picks made for BTAI stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BTAI

Corporate Flights

Flights by private jets registered to BTAI